{"title":"静脉注射免疫球蛋白治疗多发性硬化。","authors":"","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>This article is an executive summary of the Blue Cross Blue Shield Technology Evaluation Center (TEC) Assessment \"Intravenous Immune Globulin for Multiple Sclerosis\" Volume 9, No. 26, 1994. The complete assessment, which includes background information, methods, formulation of the assessment, review of evidence, conclusions, and references are available to Blue Cross Blue Shield TEC Program subscribers only. For subscription information, contact the program at (312) 440-6080.</p>","PeriodicalId":80184,"journal":{"name":"Tecnologica (Chicago, Ill.)","volume":" ","pages":"10"},"PeriodicalIF":0.0000,"publicationDate":"1995-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intravenous immune globulin for multiple sclerosis.\",\"authors\":\"\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This article is an executive summary of the Blue Cross Blue Shield Technology Evaluation Center (TEC) Assessment \\\"Intravenous Immune Globulin for Multiple Sclerosis\\\" Volume 9, No. 26, 1994. The complete assessment, which includes background information, methods, formulation of the assessment, review of evidence, conclusions, and references are available to Blue Cross Blue Shield TEC Program subscribers only. For subscription information, contact the program at (312) 440-6080.</p>\",\"PeriodicalId\":80184,\"journal\":{\"name\":\"Tecnologica (Chicago, Ill.)\",\"volume\":\" \",\"pages\":\"10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1995-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tecnologica (Chicago, Ill.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tecnologica (Chicago, Ill.)","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Intravenous immune globulin for multiple sclerosis.
This article is an executive summary of the Blue Cross Blue Shield Technology Evaluation Center (TEC) Assessment "Intravenous Immune Globulin for Multiple Sclerosis" Volume 9, No. 26, 1994. The complete assessment, which includes background information, methods, formulation of the assessment, review of evidence, conclusions, and references are available to Blue Cross Blue Shield TEC Program subscribers only. For subscription information, contact the program at (312) 440-6080.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
